Targeting obesity for therapeutic intervention in heart failure patients.
Ryosuke SatoStephan von HaehlingPublished in: Expert review of cardiovascular therapy (2024)
The STEP HFpEF (Semaglutide Treatment Effect in People with obesity and HFpEF) and SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) trials recently demonstrated that the glucagon-like peptide 1 analogue, semaglutide, improves various aspects of clinical outcomes in obese HFpEF patients and significantly reduces cardiovascular and heart failure events in non-diabetic obese patients, along with a substantial weight loss. Future clinical trials with other incretin mimetics with more potent weight loss and sub-analyses of the SELECT trial may further emphasize the importance of the obesity phenotype-based approach in the treatment of HFpEF.
Keyphrases
- weight loss
- bariatric surgery
- obese patients
- roux en y gastric bypass
- gastric bypass
- clinical trial
- heart failure
- weight gain
- ejection fraction
- metabolic syndrome
- type diabetes
- end stage renal disease
- insulin resistance
- glycemic control
- randomized controlled trial
- chronic kidney disease
- phase ii
- prognostic factors
- body mass index
- combination therapy
- drug delivery
- placebo controlled